Mersana Therapeutics share price today

(MRSN)

Mersana Therapeutics share price is $1.62 & ₹138.02 as on 25 Dec 2024, 2.30 'hrs' IST

$1.62

▲

0.09

(5.88%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Mersana Therapeutics share price in Dollar and Rupees. Guide to invest in Mersana Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Mersana Therapeutics. Get details on the Indian mutual funds that are investing in Mersana Therapeutics. Get Analyst recommendations and forecasts along with all the Mersana Therapeutics's financials.

Mersana Therapeutics share price movements

Today's Low: $1.47
Today's High: $1.66
$1.62
9.26%
Downside
Day's Volatility :11.45%
Upside
2.41%
52 Weeks Low: $1.22
52 Weeks High: $6.28
$1.62
24.69%
Downside
52 Weeks Volatility :80.57%
Upside
74.2%

Mersana Therapeutics Returns

Period	Mersana Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-12.43%	-9.0%	0.0%
6 Months	-18.8%	-4.6%	0.0%
1 Year	-28.95%	3.0%	0.0%
3 Years	-72.82%	0.0%	-21.1%

Mersana Therapeutics Key Statistics

in dollars & INR

Previous Close	$1.53
Open	$1.53
Today's High	$1.66
Today's Low	$1.47
Market Capitalization	$200.1M
Today's Volume	$494.5K
52 Week High	$6.2801
52 Week Low	$1.22
Revenue TTM	$34.8M
EBITDA	$-77.8M
Earnings Per Share (EPS)	$-0.6
Profit Margin	-214.2%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-213.33%

How to invest in Mersana Therapeutics from India?

It is very easy for Indian residents to invest directly in Mersana Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Mersana Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Mersana Therapeutics or MRSN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Mersana Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Mersana Therapeutics shares which would translate to 0.526 fractional shares of Mersana Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Mersana Therapeutics, in just a few clicks!

Returns in Mersana Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Mersana Therapeutics investment value today

Current value as on today

₹73,291

Returns

₹26,709

(-26.71%)

Returns from Mersana Therapeutics Stock

₹28,947 (-28.95%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Mersana Therapeutics

-7%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Mersana Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 26, 2024. -7% less investors are searching Mersana Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Mersana Therapeutics

EcoR1 Capital, LLC
15.68%
Nextech Invest AG
9.77%
VR Adviser, LLC
9.17%
Bain Capital Life Sciences Investors, LLC
7.01%
BlackRock Inc
6.79%
Vanguard Group Inc
5.81%

Analyst Recommendation on Mersana Therapeutics

Buy

80%Buy

20%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Mersana Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Mersana Therapeutics

What analysts predicted

Upside of 301.23%

Current:

$1.62

Target:

$6.50

Insights on Mersana Therapeutics

Price Movement
In the last 7 days, MRSN stock has moved down by -6.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 2.29M → 12.59M (in $), with an average increase of 81.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -24.26M → -11.50M (in $), with an average increase of 111.0% per quarter
MRSN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 52.9%
MRSN vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 99.4%
Price to Sales
ForMRSN every $1 of sales, investors are willing to pay $5.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Mersana Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$10.6M	↓ 39.62%
Net Income	$-64.3M	↑ 66.01%
Net Profit Margin	-606.54%	↓ 385.92%

	FY19	Y/Y Change
Revenue	$42.1M	↑ 297.61%
Net Income	$-27.2M	↓ 57.67%
Net Profit Margin	-64.57%	↑ 541.97%

	FY20	Y/Y Change
Revenue	$828.0K	↓ 98.03%
Net Income	$-88.4M	↑ 225.05%
Net Profit Margin	-10.7K%	↓ 10612.24%

	FY21	Y/Y Change
Revenue	$43.0K	↓ 94.81%
Net Income	$-169.2M	↑ 91.4%
Net Profit Margin	-393.5K%	↓ 382823.19%

	FY22	Y/Y Change
Revenue	$26.6M	↑ 61716.28%
Net Income	$-207.5M	↑ 22.66%
Net Profit Margin	-780.78%	↑ 392719.22%

	FY23	Y/Y Change
Revenue	$36.9M	↑ 38.65%
Net Income	$-171.7M	↓ 17.28%
Net Profit Margin	-465.8%	↑ 314.98%

	Q2 FY23	Q/Q Change
Revenue	$10.7M	↑ 36.55%
Net Income	$-54.3M	↓ 4.97%
Net Profit Margin	-509.73%	↑ 222.72%

	Q3 FY23	Q/Q Change
Revenue	$7.7M	↓ 27.75%
Net Income	$-41.7M	↓ 23.3%
Net Profit Margin	-541.13%	↓ 31.4%

	Q4 FY23	Q/Q Change
Revenue	$10.7M	↑ 39.01%
Net Income	$-19.5M	↓ 53.08%
Net Profit Margin	-182.64%	↑ 358.49%

	Q1 FY24	Q/Q Change
Revenue	$9.2M	↓ 13.61%
Net Income	$-19.3M	↓ 1.22%
Net Profit Margin	-208.83%	↓ 26.19%

	Q2 FY24	Q/Q Change
Revenue	$2.3M	↓ 75.2%
Net Income	$-24.3M	↑ 25.7%
Net Profit Margin	-1.1K%	↓ 849.52%

	Q3 FY24	Q/Q Change
Revenue	$12.6M	↑ 449.41%
Net Income	$-11.5M	↓ 52.61%
Net Profit Margin	-91.29%	↑ 967.06%

	FY18	Y/Y Change
Profit	$10.6M	↓ 39.62%

	FY19	Y/Y Change
Profit	$-12.9M	↓ 221.93%

	FY20	Y/Y Change
Profit	$-66.2M	↑ 412.56%

	FY21	Y/Y Change
Profit	$-132.0M	↑ 99.33%

	FY22	Y/Y Change
Profit	$25.7M	↓ 119.44%

	FY23	Y/Y Change
Profit	$-111.4M	↓ 534.29%

	Q2 FY23	Q/Q Change
Profit	$10.3M	↑ 38.05%

	Q3 FY23	Q/Q Change
Profit	$7.3M	↓ 29.61%

	Q4 FY23	Q/Q Change
Profit	$10.3M	↑ 41.03%

	Q1 FY24	Q/Q Change
Profit	$8.8M	↓ 13.97%

	Q2 FY24	Q/Q Change
Profit	$-15.0M	↓ 269.49%

	Q3 FY24	Q/Q Change
Profit	$12.6M	↓ 184.26%

	FY18	Y/Y Change
Operating Cash Flow	$-55.2M	↑ 29.38%
Investing Cash Flow	$87.2M	↓ 187.52%
Financing Cash Flow	$1.1M	↓ 98.45%

	FY19	Y/Y Change
Operating Cash Flow	$-67.7M	↑ 22.69%
Investing Cash Flow	$-27.3M	↓ 131.3%
Financing Cash Flow	$97.7M	↑ 9082.71%

	FY20	Y/Y Change
Operating Cash Flow	$-74.7M	↑ 10.26%
Investing Cash Flow	$37.0M	↓ 235.66%
Financing Cash Flow	$230.4M	↑ 135.83%

	FY21	Y/Y Change
Operating Cash Flow	$-140.0M	↑ 87.41%
Investing Cash Flow	$-648.0K	↓ 101.75%
Financing Cash Flow	$63.6M	↓ 72.38%

	FY22	Y/Y Change
Operating Cash Flow	$-49.4M	↓ 64.74%
Investing Cash Flow	$-152.7M	↑ 23467.28%
Financing Cash Flow	$153.0M	↑ 140.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-61.8M	↑ 113.18%
Investing Cash Flow	$-5.4M	↓ 489.61%
Financing Cash Flow	$73.2M	↑ 239.6%

Mersana Therapeutics Technicals Summary

Sell

Neutral

Buy

Mersana Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Mersana Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Mersana Therapeutics Inc	-25.35%	-18.8%	-28.95%	-72.82%	-68.94%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Mersana Therapeutics Inc	NA	NA	0.0	-0.59	-2.13	-0.26	NA	0.31
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Mersana Therapeutics Inc	Buy	$200.1M	-68.94%	NA	-214.2%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Mersana Therapeutics

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Organization	Mersana Therapeutics
Employees	123
CEO	Dr. Martin H. Huber M.D.
Industry	Health Technology

Management People of Mersana Therapeutics

Name	Title
Dr. Martin H. Huber M.D.	President, CEO & Director
Mr. Brian C. DeSchuytner	Senior VP, CFO & COO
Dr. Timothy B. Lowinger Ph.D.	Senior VP and Chief Science & Technology Officer
Ms. Alejandra Veronica Carvajal J.D.	Senior VP, Secretary & Chief Legal Officer
Mr. Mohan Bala Ph.D.	Senior VP & Chief Development Officer
Mr. Mikhail Papisov Ph.D.	Co-Founder
Mr. Ashish Mandelia	Chief Accounting Officer
Mr. Jason Fredette	Senior Vice President of Investor Relations & Corporate Communications
Mr. Chuck Miller	Senior Vice President of Regulatory Affairs

Important FAQs about investing in Mersana Therapeutics from India :

What is Mersana Therapeutics share price today?

Mersana Therapeutics share price today stands at $1.62, Open: $1.53 ; Previous Close: $1.53 ; High: $1.66 ; Low: $1.47 ; 52 Week High: $6.28 ; 52 Week Low: $1.22. The stock opens at $1.53, after a previous close of $1.53. The stock reached a daily high of $1.66 and a low of $1.47, with a 52-week high of $6.28 and a 52-week low of $1.22.

Can Indians buy Mersana Therapeutics shares?

Yes, Indians can invest in the Mersana Therapeutics (MRSN) from India.

With INDmoney, you can buy Mersana Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Mersana Therapeutics at zero transaction cost.

How can I buy Mersana Therapeutics shares from India?

It is very easy to buy Mersana Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Mersana Therapeutics be purchased?

Yes, you can buy fractional shares of Mersana Therapeutics with INDmoney app.

What are the documents required to start investing in Mersana Therapeutics stocks?

To start investing in Mersana Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.